Literature DB >> 6220104

Polymorphonuclear neutrophils express the common acute lymphoblastic leukemia antigen.

J Cossman, L M Neckers, W J Leonard, W C Greene.   

Abstract

Monoclonal antibodies J5, VIL-A1, and BA-3, known to react with the common acute lymphoblastic leukemia antigen (CALLA) were found to specifically stain normal human polymorphonuclear neutrophils (PMN). The antigen detected on PMN had a molecular weight (95,000-110,000 mol wt) close to that of CALLA (95,000-100,000 mol wt) and thus these surface membrane antigens are likely related, if not identical. The fluorescent staining intensity of PMN is comparable to that of CALLA-positive leukemic cells and the presence of PMN in patient samples could potentially produce false-positive results in diagnosis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6220104      PMCID: PMC2186955          DOI: 10.1084/jem.157.3.1064

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  12 in total

1.  Simple and rapid measurement of human T lymphocytes and their subclasses in peripheral blood.

Authors:  R A Hoffman; P C Kung; W P Hansen; G Goldstein
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

2.  Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents.

Authors:  E Huberman; M F Callaham
Journal:  Proc Natl Acad Sci U S A       Date:  1979-03       Impact factor: 11.205

3.  Analysis of human leukemia/lymphoma cell lines with monoclonal antibodies BA-1, BA-2 and BA-3.

Authors:  T LeBien; J Kersey; S Nakazawa; K Minato; J Minowada
Journal:  Leuk Res       Date:  1982       Impact factor: 3.156

4.  Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro.

Authors:  T W Lebien; D R Boué; J G Bradley; J H Kersey
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

5.  Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage.

Authors:  J Ritz; L M Nadler; A K Bhan; J Notis-McConarty; J M Pesando; S F Schlossman
Journal:  Blood       Date:  1981-09       Impact factor: 22.113

6.  A monoclonal antibody to human acute lymphoblastic leukaemia antigen.

Authors:  J Ritz; J M Pesando; J Notis-McConarty; H Lazarus; S F Schlossman
Journal:  Nature       Date:  1980-02-07       Impact factor: 49.962

7.  Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds.

Authors:  S J Collins; F W Ruscetti; R E Gallagher; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1978-05       Impact factor: 11.205

8.  Serotherapy of acute lymphoblastic leukemia with monoclonal antibody.

Authors:  J Ritz; J M Pesando; S E Sallan; L A Clavell; J Notis-McConarty; P Rosenthal; S F Schlossman
Journal:  Blood       Date:  1981-07       Impact factor: 22.113

9.  Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors.

Authors:  L A Clavell; J M Lipton; R C Bast; M Kudisch; J Pesando; S F Scholssman; J Ritz
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

10.  Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues.

Authors:  R S Metzgar; M J Borowitz; N H Jones; B L Dowell
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

View more
  23 in total

1.  Flow cytometric study of neutrophilic granulopoiesis in normal bone marrow using an expanded panel of antibodies: correlation with morphologic assessments.

Authors:  M Tarek Elghetany; Yimin Ge; Jyoti Patel; Joe Martinez; Hanna Uhrova
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

2.  Tonsillar mapping of determinants found on normal lymphoreticular (T,B,K, immature and macrophage) and myeloblastic leukemia cells.

Authors:  E M McMillan; L Stoneking; G B Humphrey; J Rapacz
Journal:  Am J Pathol       Date:  1987-03       Impact factor: 4.307

3.  A new method for high speed, sensitive detection of minimal residual disease.

Authors:  Xiaohe Liu; H Ben Hsieh; Dario Campana; Richard H Bruce
Journal:  Cytometry A       Date:  2011-09-13       Impact factor: 4.355

4.  CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung.

Authors:  M A Shipp; G E Tarr; C Y Chen; S N Switzer; L B Hersh; H Stein; M E Sunday; E L Reinherz
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

5.  Granulocyte colony-stimulating factor-induced terminal maturation of human myeloid cells is specifically associated with up-regulation of receptor-mediated function and CD10 expression.

Authors:  Yuko Inazawa; Kumiko Saeki; Akira Yuo
Journal:  Int J Hematol       Date:  2003-02       Impact factor: 2.490

6.  Identification of human neutrophils during experimentally induced inflammation in mice with transplanted CD34+ cells from human umbilical cord blood.

Authors:  Masaru Doshi; Makoto Koyanagi; Masako Nakahara; Koichi Saeki; Kumiko Saeki; Akira Yuo
Journal:  Int J Hematol       Date:  2006-10       Impact factor: 2.490

7.  Phenotypic expression of B-lymphocytes. 1. Identification with monoclonal antibodies in normal lymphoid tissues.

Authors:  S M Hsu; E S Jaffe
Journal:  Am J Pathol       Date:  1984-03       Impact factor: 4.307

8.  Characterization of neutral endopeptidase 24.11 in dog glomeruli.

Authors:  C Landry; P Santagata; W Bawab; M C Fournié-Zaluski; B P Roques; P Vinay; P Crine
Journal:  Biochem J       Date:  1993-05-01       Impact factor: 3.857

9.  Inhibition of CD10/neutral endopeptidase 24.11 promotes B-cell reconstitution and maturation in vivo.

Authors:  G Salles; H R Rodewald; B S Chin; E L Reinherz; M A Shipp
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

10.  The increase of low density subpopulations and CD10 (CALLA) negative neutrophils in severely infected patients.

Authors:  T Morisaki; T Goya; T Ishimitsu; M Torisu
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.